The Tumor Microenvironment

1. Front Matter

   Pages i-xviii

   PDF

2. Physiological Parameters

   1. Front Matter

      Pages 1-1

      PDF

   2. Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy

      • Annamaria Rapisarda, Giovanni Melillo

      Pages 3-21

   3. The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases

      • Pawel Swietach, Adrian L. Harris, Richard D. Vaughan-Jones

      Pages 23-41

   4. Hypoxia, Gene Expression, and Metastasis

      • Olga V. Razorenova, Amato J. Giaccia

      Pages 43-58

   5. Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX

      • Jaromir Pastorek, Silvia Pastorekova

      Pages 59-90

   6. Glycolytic Pathway as a Target for Tumor Inhibition

      • Weiqin Lu, Peng Huang

      Pages 91-118

3. Malignant Cells

   1. Front Matter

      Pages 119-119

      PDF

   2. Aberrant DNA Methylation in Cancer Cells

      • Toshikazu Ushijima

      Pages 121-132

   3. DNA Repair and Redox Signaling

      • Mark R. Kelley, Millie M. Georgiadis, Melissa L. Fishel

      Pages 133-168

   4. Cancer Stem Cells and Microenvironment

      • Mario Federico, Antonio Giordano

      Pages 169-185

   5. Epithelial–Mesenchymal Transition in Development and Diseases

      • Yadi Wu, Binhua P. Zhou

      Pages 187-211

   6. Invasion and Metastasis

      • Douglas M. Noonan, Giuseppina Pennesi, Adriana Albini

      Pages 213-228

   7. Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment

      • Paloma Bragado, Aparna C. Ranganathan, Julio A. Aguirre-Ghiso

      Pages 229-254

4. Vasculature And Stroma

   1. Front Matter

      Pages 255-255

      PDF

   2. Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy

      • Robert S. Kerbel, Francesco Bertolini, Yuval Shaked

      Pages 257-273

   3. Bone Marrow Derived Mesenchymal Stem/Stromal Cells and Tumor Growth

      • Pravin J. Mishra, Debabrata Banerjee

      Pages 275-288

   4. Integrin Signaling in Lymphangiogenesis

      • Barbara Garmy-Susini

      Pages 289-309

   5. Role of Pericytes in Resistance to Antiangiogenic Therapy

      • Koji Matsuo, Chunhua Lu, Mian M. K. Shazad, Robert L. Coleman, Anil K. Sood

      Pages 311-323

   6. Tumour-Promoting Stromal Myofibroblasts in Human Carcinomas

      • Urszula M. Polanska, Kieran T. Mellody, Akira Orimo

      Pages 325-349

The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer re- lators was the recognition that lymphocytes can participate in what was termed “immune surveillance” in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies sh- ing the potential use of immune-based therapies in cancer treatment.

• Chemokine
• DNA
• angiogenesis
• cancer therapy
• carcinogenesis
• carcinoma
• cell
• immunotherapy
• lymphocytes
• macrophages
• metastasis
• methylation
• research
• tumor
• tumor growth

• Genzyme Corporation, Framingham, USA

  Rebecca G. Bagley

Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.

Policies and ethics